Common Side Effects of Humira Biosimilars
Humira (adalimumab), a TNF inhibitor for autoimmune conditions like rheumatoid arthritis and psoriasis, has several biosimilars approved in the US and Europe, including Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd), and Yusimry (adalimumab-aqvh). These copy drugs have side effect profiles nearly identical to Humira's due to their structural similarity and equivalent clinical trials.[1][2]
The most frequent side effects, occurring in >10% of patients across trials, are:
- Injection site reactions (redness, itching, pain, or swelling at the site).
- Upper respiratory infections (sinus issues, colds).
- Headache.
- Rash.
These match Humira's label exactly, as biosimilars must demonstrate no meaningful clinical differences.[3]
How Side Effects Compare to Original Humira
No significant differences exist. FDA approvals for US biosimilars relied on pharmacokinetic studies and immunogenicity data showing equivalent safety. Post-marketing data from Europe, where biosimilars launched earlier (2018 vs. US 2023), confirms rates like injection site reactions at 10-20% and infections at 15-25%, aligning with Humira's 20+ years of data.[1][4]
| Side Effect | Humira Rate | Biosimilar Average Rate (e.g., Amjevita, Cyltezo) |
|-------------|-------------|--------------------------------------------------|
| Injection site reactions | 14-20% | 12-18% |
| Upper respiratory infections | 17% | 15-20% |
| Headache | 12% | 10-14% |
| Rash | 11% | 9-12% |
Serious Risks Patients Report Most
Less common but highlighted in patient forums and labels (<5% incidence):
- Serious infections (tuberculosis reactivation, sepsis).
- Allergic reactions or hypersensitivity.
- Liver enzyme elevations.
Biosimilars carry the same black box warning for infections and malignancy risk as Humira. Real-world evidence from over 100,000 patients shows no increased rates.[2][5]
Why Do Injection Site Reactions Happen More with Biosimilars?
Slightly higher reports in some early switch studies (e.g., 2-3% variance) stem from no interchangeable citrate-free formulations in all versions—patients switching may notice temporary differences in injection comfort. This fades after 1-2 doses.[4]
Which Biosimilar Might Have Fewer Reports?
Cyltezo and Yusimry, with high-concentration citrate-free options like Humira's latest version, report marginally lower injection site issues (8-12%) in trials. Patient reviews on Drugs.com echo this for comfort.[3][6]
When Do Side Effects Peak and Fade?
Most (e.g., infections, headache) appear within the first 4-12 weeks, resolving or stabilizing by month 6. Monitor closely during initiation, regardless of brand.[1]
[1]: FDA Humira Biosimilar Approvals
[2]: EMA Adalimumab Biosimilar Assessment Reports
[3]: Amjevita Prescribing Information
[4]: Drugs.com - Humira vs Biosimilars Side Effects
[5]: PubMed - Adalimumab Biosimilar Safety Meta-Analysis
[6]: DrugPatentWatch.com - Humira Biosimilars